Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: A case series illustrating utility in clinical practice

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 2, 2010, Pages 149-151

  Mazumder, Amitabha ^a   Vesole, David H ^b   Jagannath, Sundar ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

HDAC; Histone deacetylase inhibitor; Proapoptotic; Proteasome inhibitor; Synergistic; Vorinostat

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; IMMUNOMODULATING AGENT; LENALIDOMIDE; VORINOSTAT; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CASE REPORT; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; RECURRENT DISEASE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE;

EID: 77954678294     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.022     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
4. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-Cell lymphoma (CTCL). Blood 2007;109:31-9.
5. Olsen EA, Kim YH, Kuzel TM, et al. Phase lib multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-Cell lymphoma. J Clin Oncol 2007;25:3109-15.
6. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-62.
7. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101:540-5.
8. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
9. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839-52.
10. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/ Abl+ cells sensitive and resistant to STI571. Blood 2003;102:3765-74.
11. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suber-oylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49:502-7.
12. Weber DM, Badros AZ, Jagannath S, et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma -early clinical experience. Blood 2008;112:322 (abstract 871).
13. Weber DM, Jagannath S, Sobecks R, et al. Combination of vorinostat plus bort-ezomib for the treatment of patients with multiple myeloma who have previously received bortezomib. Blood 2008;112:1272 (abstract 3711).
14. Mitsiades CS, Hayden PJ, Anderson KC, et al. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pact Res Clin Haematol 2007;20:797-816.
15. Badros A, Philip S, Nlesvizky R, et al. Phase I trial of vorinostat plus bortezomib (bort) in relapsed and refractory multiple myeloma (MM) patients (pts). Haematologica 2008;93: (abstract 0642).
16. Nawrocki ST, Carew JS, Maclean KH, et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008;112:2917-26.
17. Fandy TE, Shankar S, Ross DD, et al. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005;7:646-57.
18. Cheriyath V, Glaser KB, Healan-Greenberg C, et al. Epigenetic regulation of IFN-a2b in multiple myeloma by a hydroxamic acid histone deacetylase (HDAC) inhibitor (SAHA) and a non-hydroxamic acid HDAC inhibitor (A-423378). JClin Oncol 2007;25(suppl):615s (abstract 14048).
19. Siegel D, Weber DM, Mitsiades CS, et al. A phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2008;112:3705 (abstract 3705).